NYSE:KDMN - Kadmon Stock Price, Forecast & News

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KDMN shares have increased by 14.7% and is now trading at $3.99. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

Kadmon is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Kadmon.

Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings results on Thursday, March, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.12. The company had revenue of $4.40 million for the quarter, compared to analysts' expectations of $2.75 million. Kadmon had a negative return on equity of 110.70% and a negative net margin of 1,204.47%. View Kadmon's earnings history.

4 brokerages have issued 12-month price targets for Kadmon's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Kadmon's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 232.1% from the stock's current price. View analysts' price targets for Kadmon.

News articles about KDMN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kadmon earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutKadmon.

Some companies that are related to Kadmon include PPD (SDGR), Myokardia (MYOK), ArQule (ARQL), Agios Pharmaceuticals (AGIO), ChemoCentryx (CCXI), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Alkermes (ALKS), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Applied Materials (AMAT), Iovance Biotherapeutics (IOVA), Biocept (BIOC), Global Blood Therapeutics (GBT), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Catalyst Pharmaceuticals (CPRX).

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Kadmon's stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (11.29%), Boxer Capital LLC (4.79%), State Street Corp (2.67%), Sofinnova Investments Inc. (1.83%), Geode Capital Management LLC (1.45%) and Nuveen Asset Management LLC (1.13%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon.

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Goldman Sachs Group Inc., Macquarie Group Ltd., Macquarie Group Ltd., Quantitative Systematic Strategies LLC, Bank of America Corp DE, Algert Global LLC, and Principal Financial Group Inc.. View insider buying and selling activity for Kadmon.

KDMN stock was bought by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, Nuveen Asset Management LLC, Schonfeld Strategic Advisors LLC, EAM Global Investors LLC, Panagora Asset Management Inc., and EAM Investors LLC. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon.

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KDMN stock can currently be purchased for approximately $3.99.

Kadmon has a market capitalization of $637.44 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe. View additional information about Kadmon.

The official website for Kadmon is http://www.kadmon.com/.

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]